Home › Companies › JAZZ PHARMACEUTICALS PLC › 2024-2025

JAZZ PHARMACEUTICALS PLC 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and JAZZ PHARMACEUTICALS PLC’s Form 8-K, filed 2024-07-26 (Item 5.07 on EDGAR). Page generated 02 October 2026.

23Reported items
551Asset managers
6,078Fund votes
2024-07-25Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore JAZZ PHARMACEUTICALS PLC in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by JAZZ PHARMACEUTICALS PLC

These tallies are JAZZ PHARMACEUTICALS PLC’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-07-26 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

JAZZ PHARMACEUTICALS PLC — official shareholder meeting results, meeting held 2024-07-25
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Laura J. Hamill	52,774,330	1,432,999	133,482	--	3,692,565	Majority: yes
Elect Director: Patrick Kennedy	52,306,399	1,901,706	132,706	--	3,692,565	Majority: yes
Elect Director: Kenneth W. O'Keefe	50,931,857	3,280,188	128,766	--	3,692,565	Majority: yes
Elect Director: Mark D. Smith, M.D.	50,507,449	3,685,604	147,758	--	3,692,565	Majority: yes
Proposal 2: to ratify, on a non-binding advisory basis, the appointment of KPMG, Dublin as our independent auditors for the fiscal year ending December 31, 2024 and to authorize, in a binding vote, our board of directors, acting through the audit committee, to	56,719,225	1,184,200	129,951	--	--	Majority: yes
Proposal 3: to approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement	49,319,464	4,780,265	241,082	--	3,692,565	Majority: yes
Proposal 5: to grant our board of directors authority under Irish law to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption right that would otherwise apply	52,568,310	5,308,898	156,168	--	--	Majority: yes

Source: JAZZ PHARMACEUTICALS PLC, Form 8-K, filed with the SEC on 2024-07-26 — read the filing on EDGAR.

How asset managers voted at the JAZZ PHARMACEUTICALS PLC 2024-2025 meeting

Each item below shows how the 551 asset managers that disclosed a JAZZ PHARMACEUTICALS PLC vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of JAZZ PHARMACEUTICALS PLC’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc's named executive officers, as disclosed in the proxy statement.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2024-07-25.

Combines 23 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%9%

FOR: 49,319,464AGAINST: 4,780,265

JAZZ PHARMACEUTICALS PLC’s own tally for this item (“Proposal 3: to approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement”): 49,319,464 for, 4,780,265 against, per its Form 8-K filed 2024-07-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 62,255,000 outstanding shares: 79% for, 8% against (87% of the company cast a for/against vote).

The 528 asset managers below cast 93% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 93%

FOR: 93.1%AGAINST: 6.7%ABSTAIN: 0.3%NOT VOTED: 0.0%

Largest asset managers voting on “To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc's named executive of” at JAZZ PHARMACEUTICALS PLC, 2024-2025
Asset manager	For	Against	Vote
BlackRock	6,485,203	501	For
Vanguard	6,414,498	0	For
Capital Group	4,020,672	0	For
Fidelity	2,792,888	0	For
State Street	2,500,349	0	For
LSV ASSET MANAGEMENT	1,652,873	0	For
JPMorgan	1,434,266	0	For
Pacer Funds Trust	1,384,214	0	For
Vestal Point Capital, LP	1,339,717	0	For
Baupost	0	1,274,248	Against
GEODE CAPITAL MANAGEMENT, LLC	1,118,631	0	For
Camber Capital Management LP	1,116,047	0	For
FRANKLIN ADVISERS INC	1,065,951	0	For
Swedbank Robur Fonder AB	0	1,016,753	Against
EcoR1 Capital, LLC	1,013,952	0	For
Dimensional	961,050	0	For
Columbia Threadneedle	957,573	0	For
Charles Schwab	907,283	0	For
THOMPSON SIEGEL & WALMSLEY LLC	619,062	0	For
FRANKLIN STRATEGIC SERIES	587,263	0	For
Northern Trust	585,035	0	For
FULLER & THALER ASSET MANAGEMENT, INC.	553,971	0	For
MELLON INVESTMENTS Corp	549,127	0	For
Capitol Series Trust	529,982	0	For
Pear Tree Funds	512,200	0	For

Showing the 25 largest of 528 asset managers. See all 528 in the interactive database.

2. To indicate, on a non-binding advisory basis, the preferred frequency of the advisory vote on the compensation of Jazz Pharmaceuticals plc's named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2024-07-25.

Combines 11 wordings of this item as funds reported it.

100% fund support · no official result

ONE YEAR 59%1 YEAR 34%

The 493 asset managers below cast 100% of the shares they voted on this item FOR (227,172 for, 0 against).

FOR: 227,172 (0.4%)ABSTAIN: 106,418 (0.2%)ONE YEAR: 31,832,625 (59.3%)1 YEAR: 18,420,693 (34.3%)1YR: 2,019,569 (3.8%)THREE YEARS: 976,133 (1.8%)3 YEARS: 65,418 (0.1%)2 YEARS: 35,939 (0.1%)1-YEAR: 26,287 (0.0%)NOT VOTED: 1,152 (0.0%)

Largest asset managers voting on “To indicate, on a non-binding advisory basis, the preferred frequency of the advisory vote on the compensation” at JAZZ PHARMACEUTICALS PLC, 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Vanguard	0	0	0	0	One Year
BlackRock	0	0	0	0	1 Year
Capital Group	0	0	0	0	1Yr
Fidelity	0	0	0	0	One Year
State Street	0	0	0	0	One Year
LSV ASSET MANAGEMENT	0	0	0	0	1 Year
Pacer Funds Trust	0	0	0	0	1 Year
Vestal Point Capital, LP	0	0	0	0	One Year
Baupost	0	0	0	0	1 Year
GEODE CAPITAL MANAGEMENT, LLC	0	0	0	0	One Year
Camber Capital Management LP	0	0	0	0	One Year
FRANKLIN ADVISERS INC	0	0	0	0	One Year
Swedbank Robur Fonder AB	0	0	0	0	One Year
EcoR1 Capital, LLC	0	0	0	0	One Year
Dimensional	0	0	0	0	Three Years
Columbia Threadneedle	0	0	0	0	One Year
Charles Schwab	0	0	0	0	1 Year
THOMPSON SIEGEL & WALMSLEY LLC	0	0	0	0	One Year
FRANKLIN STRATEGIC SERIES	0	0	0	0	One Year
Northern Trust	0	0	0	0	1 Year
FULLER & THALER ASSET MANAGEMENT, INC.	0	0	0	0	One Year
MELLON INVESTMENTS Corp	0	0	0	0	One Year
Pear Tree Funds	0	0	0	0	1 Year
John Hancock	0	0	0	0	One Year
SEI	0	0	0	0	1 Year

Showing the 25 largest of 493 asset managers. See all 493 in the interactive database.

3. To ratify, on a non-binding advisory basis, the appointment of KPMG as the independent auditors of Jazz Pharmaceuticals plc for the fiscal year ending December 31, 2024 and to authorize, in a binding vote, the Board of Directors, acting through the audit committee, to determine KPMG's remuneration.

AUDIT-RELATEDMajority of the votes cast: yes

Meeting held 2024-07-25.

Combines 6 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 56,719,225AGAINST: 1,184,200

JAZZ PHARMACEUTICALS PLC’s own tally for this item (“Proposal 2: to ratify, on a non-binding advisory basis, the appointment of KPMG, Dublin as our independent auditors for the fiscal year ending December 31, 2024 and to authorize, in a binding vote, our board of directors”): 56,719,225 for, 1,184,200 against, per its Form 8-K filed 2024-07-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 62,255,000 outstanding shares: 91% for, 2% against (93% of the company cast a for/against vote).

The 123 asset managers below cast 99.3% of the shares they voted on this item FOR (23,045,874 for, 149,013 against).

FOR 99.2%

FOR: 23,045,874 (99.3%)AGAINST: 149,013 (0.6%)ABSTAIN: 13,987 (0.1%)

Largest asset managers voting on “To ratify, on a non-binding advisory basis, the appointment of KPMG as the independent auditors of Jazz Pharma” at JAZZ PHARMACEUTICALS PLC, 2024-2025
Asset manager	For	Against	Vote
Vanguard	6,172,417	0	For
BlackRock	3,340,428	0	For
Capital Group	2,000,000	0	For
Fidelity	1,860,787	0	For
Pacer Funds Trust	1,384,214	0	For
Columbia Threadneedle	949,636	0	For
Dimensional	723,171	0	For
FRANKLIN STRATEGIC SERIES	587,263	0	For
Capitol Series Trust	529,982	0	For
Pear Tree Funds	512,200	0	For
State Street	495,031	0	For
Charles Schwab	451,732	0	For
Transamerica	378,261	0	For
TIAA	352,728	0	For
First Trust	231,775	0	For
SEI	217,100	7,319	For
Bridge Builder Trust	211,351	0	For
AIG/SunAmerica	199,792	0	For
Federated Hermes	192,148	0	For
John Hancock	160,308	0	For
Jackson National	141,257	0	For
ETF Series Solutions	0	125,584	Against
Equitable	109,187	0	For
Voya	90,093	0	For
American Century	90,086	0	For

Showing the 25 largest of 123 asset managers. See all 123 in the interactive database.

4. To elect four nominees for director named below to hold office until the 2027 Annual General Meeting of Shareholders: Kenneth W. O'Keefe

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-07-25.

Combines 4 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 50,931,857AGAINST: 3,280,188

JAZZ PHARMACEUTICALS PLC’s own tally for this item (“Elect Director: Kenneth W. O'Keefe”): 50,931,857 for, 3,280,188 against, per its Form 8-K filed 2024-07-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 62,255,000 outstanding shares: 82% for, 5% against (87% of the company cast a for/against vote).

The 120 asset managers below cast 99% of the shares they voted on this item FOR (22,959,753 for, 236,488 against).

FOR 99%

FOR: 22,959,753 (98.9%)AGAINST: 236,488 (1.0%)ABSTAIN: 12,631 (0.1%)

Largest asset managers voting on “To elect four nominees for director named below to hold office until the 2027 Annual General Meeting of Shareh” at JAZZ PHARMACEUTICALS PLC, 2024-2025
Asset manager	For	Against	Vote
Vanguard	6,172,417	0	For
BlackRock	3,340,428	0	For
Capital Group	2,000,000	0	For
Fidelity	1,860,787	0	For
Pacer Funds Trust	1,384,214	0	For
Columbia Threadneedle	949,636	0	For
Dimensional	723,171	0	For
FRANKLIN STRATEGIC SERIES	587,263	0	For
Capitol Series Trust	529,982	0	For
Pear Tree Funds	512,200	0	For
State Street	495,031	0	For
Charles Schwab	451,732	0	For
Transamerica	378,261	0	For
TIAA	352,728	0	For
First Trust	231,775	0	For
SEI	224,419	0	For
Bridge Builder Trust	211,351	0	For
AIG/SunAmerica	199,792	0	For
Federated Hermes	192,148	0	For
John Hancock	160,308	0	For
Jackson National	141,257	0	For
ETF Series Solutions	0	125,584	Against
Equitable	29,441	79,746	Against
Voya	90,093	0	For
American Century	90,086	0	For

Showing the 25 largest of 120 asset managers. See all 120 in the interactive database.

5. To elect four nominees for director named below to hold office until the 2027 Annual General Meeting of Shareholders: Laura J. Hamill

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-07-25.

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 52,774,330AGAINST: 1,432,999

JAZZ PHARMACEUTICALS PLC’s own tally for this item (“Elect Director: Laura J. Hamill”): 52,774,330 for, 1,432,999 against, per its Form 8-K filed 2024-07-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 62,255,000 outstanding shares: 85% for, 2% against (87% of the company cast a for/against vote).

The 120 asset managers below cast 99.9% of the shares they voted on this item FOR (23,194,845 for, 1,396 against).

FOR 99.9%

FOR: 23,194,845 (99.9%)AGAINST: 1,396 (0.0%)ABSTAIN: 12,631 (0.1%)

Largest asset managers voting on “To elect four nominees for director named below to hold office until the 2027 Annual General Meeting of Shareh” at JAZZ PHARMACEUTICALS PLC, 2024-2025
Asset manager	For	Vote
Vanguard	6,172,417	For
BlackRock	3,340,428	For
Capital Group	2,000,000	For
Fidelity	1,860,787	For
Pacer Funds Trust	1,384,214	For
Columbia Threadneedle	949,636	For
Dimensional	723,171	For
FRANKLIN STRATEGIC SERIES	587,263	For
Capitol Series Trust	529,982	For
Pear Tree Funds	512,200	For
State Street	495,031	For
Charles Schwab	451,732	For
Transamerica	378,261	For
TIAA	352,728	For
First Trust	231,775	For
SEI	224,419	For
Bridge Builder Trust	211,351	For
AIG/SunAmerica	199,792	For
Federated Hermes	192,148	For
John Hancock	160,308	For
Jackson National	141,257	For
ETF Series Solutions	125,584	For
Equitable	109,187	For
Voya	90,093	For
American Century	90,086	For

Showing the 25 largest of 120 asset managers. See all 120 in the interactive database.

6. To elect four nominees for director named below to hold office until the 2027 Annual General Meeting of Shareholders: Mark D. Smith, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-07-25.

Combines 3 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%

FOR: 50,507,449AGAINST: 3,685,604

JAZZ PHARMACEUTICALS PLC’s own tally for this item (“Elect Director: Mark D. Smith, M.D.”): 50,507,449 for, 3,685,604 against, per its Form 8-K filed 2024-07-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 62,255,000 outstanding shares: 81% for, 6% against (87% of the company cast a for/against vote).

The 120 asset managers below cast 99% of the shares they voted on this item FOR (22,937,894 for, 258,347 against).

FOR 99%

FOR: 22,937,894 (98.8%)AGAINST: 258,347 (1.1%)ABSTAIN: 12,631 (0.1%)

Largest asset managers voting on “To elect four nominees for director named below to hold office until the 2027 Annual General Meeting of Shareh” at JAZZ PHARMACEUTICALS PLC, 2024-2025
Asset manager	For	Against	Vote
Vanguard	6,172,417	0	For
BlackRock	3,340,428	0	For
Capital Group	2,000,000	0	For
Fidelity	1,860,787	0	For
Pacer Funds Trust	1,384,214	0	For
Columbia Threadneedle	949,636	0	For
Dimensional	723,171	0	For
FRANKLIN STRATEGIC SERIES	587,263	0	For
Capitol Series Trust	529,982	0	For
Pear Tree Funds	512,200	0	For
State Street	495,031	0	For
Charles Schwab	451,732	0	For
Transamerica	378,261	0	For
TIAA	352,728	0	For
First Trust	231,775	0	For
SEI	224,419	0	For
Bridge Builder Trust	211,351	0	For
AIG/SunAmerica	199,792	0	For
Federated Hermes	192,148	0	For
John Hancock	160,308	0	For
Jackson National	141,257	0	For
ETF Series Solutions	125,584	0	For
Equitable	29,441	79,746	Against
Voya	90,093	0	For
American Century	90,086	0	For

Showing the 25 largest of 120 asset managers. See all 120 in the interactive database.

7. To elect four nominees for director named below to hold office until the 2027 Annual General Meeting of Shareholders: Patrick Kennedy

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2024-07-25.

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 52,306,399AGAINST: 1,901,706

JAZZ PHARMACEUTICALS PLC’s own tally for this item (“Elect Director: Patrick Kennedy”): 52,306,399 for, 1,901,706 against, per its Form 8-K filed 2024-07-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 62,255,000 outstanding shares: 84% for, 3% against (87% of the company cast a for/against vote).

The 120 asset managers below cast 99.9% of the shares they voted on this item FOR (23,194,845 for, 1,396 against).

FOR 99.9%

FOR: 23,194,845 (99.9%)AGAINST: 1,396 (0.0%)ABSTAIN: 12,631 (0.1%)

Largest asset managers voting on “To elect four nominees for director named below to hold office until the 2027 Annual General Meeting of Shareh” at JAZZ PHARMACEUTICALS PLC, 2024-2025
Asset manager	For	Vote
Vanguard	6,172,417	For
BlackRock	3,340,428	For
Capital Group	2,000,000	For
Fidelity	1,860,787	For
Pacer Funds Trust	1,384,214	For
Columbia Threadneedle	949,636	For
Dimensional	723,171	For
FRANKLIN STRATEGIC SERIES	587,263	For
Capitol Series Trust	529,982	For
Pear Tree Funds	512,200	For
State Street	495,031	For
Charles Schwab	451,732	For
Transamerica	378,261	For
TIAA	352,728	For
First Trust	231,775	For
SEI	224,419	For
Bridge Builder Trust	211,351	For
AIG/SunAmerica	199,792	For
Federated Hermes	192,148	For
John Hancock	160,308	For
Jackson National	141,257	For
ETF Series Solutions	125,584	For
Equitable	109,187	For
Voya	90,093	For
American Century	90,086	For

Showing the 25 largest of 120 asset managers. See all 120 in the interactive database.

8. To grant the Board of Directors authority under Irish law to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre- emption right that would otherwise apply.

CAPITAL STRUCTUREMajority of the votes cast: yes

Meeting held 2024-07-25.

Combines 3 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%9%

FOR: 52,568,310AGAINST: 5,308,898

JAZZ PHARMACEUTICALS PLC’s own tally for this item (“Proposal 5: to grant our board of directors authority under Irish law to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emptio”): 52,568,310 for, 5,308,898 against, per its Form 8-K filed 2024-07-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 62,255,000 outstanding shares: 84% for, 9% against (93% of the company cast a for/against vote).

The 119 asset managers below cast 96% of the shares they voted on this item FOR (22,172,268 for, 999,887 against).

FOR 96%

FOR: 22,172,268 (95.7%)AGAINST: 999,887 (4.3%)

Largest asset managers voting on “To grant the Board of Directors authority under Irish law to allot and issue ordinary shares for cash without ” at JAZZ PHARMACEUTICALS PLC, 2024-2025
Asset manager	For	Against	Vote
Vanguard	6,172,417	0	For
BlackRock	3,340,428	0	For
Capital Group	2,000,000	0	For
Fidelity	1,860,787	0	For
Pacer Funds Trust	1,384,214	0	For
Columbia Threadneedle	0	949,636	Against
Dimensional	723,171	0	For
FRANKLIN STRATEGIC SERIES	587,263	0	For
Capitol Series Trust	529,982	0	For
Pear Tree Funds	512,200	0	For
State Street	495,031	0	For
Charles Schwab	451,732	0	For
Transamerica	378,261	0	For
TIAA	352,728	0	For
First Trust	231,775	0	For
SEI	224,419	0	For
Bridge Builder Trust	211,351	0	For
AIG/SunAmerica	199,792	0	For
Federated Hermes	192,148	0	For
John Hancock	160,308	0	For
Jackson National	141,257	0	For
ETF Series Solutions	125,584	0	For
Equitable	109,187	0	For
Voya	90,093	0	For
American Century	90,086	0	For

Showing the 25 largest of 119 asset managers. See all 119 in the interactive database.

9. To approve any motion to adjourn the Annual General Meeting, or any adjournments thereof, to another time and place to solicit additional proxies if there are insufficient votes at the time of the Annual General Meeting to approve Proposal 5.

CORPORATE GOVERNANCE

Meeting held 2024-07-25.

Combines 2 wordings of this item as funds reported it.

94% fund support · no official result

FOR 94%

The 118 asset managers below cast 94% of the shares they voted on this item FOR (21,672,583 for, 1,486,941 against).

FOR: 21,672,583 (93.5%)AGAINST: 1,486,941 (6.4%)ABSTAIN: 12,631 (0.1%)

Largest asset managers voting on “To approve any motion to adjourn the Annual General Meeting, or any adjournments thereof, to another time and ” at JAZZ PHARMACEUTICALS PLC, 2024-2025
Asset manager	For	Against	Vote
Vanguard	6,172,417	0	For
BlackRock	3,340,428	0	For
Capital Group	2,000,000	0	For
Fidelity	1,860,787	0	For
Pacer Funds Trust	1,384,214	0	For
Columbia Threadneedle	0	949,636	Against
Dimensional	723,171	0	For
FRANKLIN STRATEGIC SERIES	587,263	0	For
Capitol Series Trust	529,982	0	For
Pear Tree Funds	512,200	0	For
State Street	0	495,031	Against
Charles Schwab	451,732	0	For
Transamerica	378,261	0	For
TIAA	352,728	0	For
First Trust	231,775	0	For
SEI	217,100	7,319	For
Bridge Builder Trust	211,351	0	For
AIG/SunAmerica	199,792	0	For
Federated Hermes	192,148	0	For
John Hancock	160,308	0	For
Jackson National	141,257	0	For
ETF Series Solutions	125,584	0	For
Equitable	109,187	0	For
Voya	90,093	0	For
American Century	90,086	0	For

Showing the 25 largest of 118 asset managers. See all 118 in the interactive database.

10. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2024-07-25.

100% fund support · no official result

ONE YEAR 99.2%

The 13 asset managers below cast 100% of the shares they voted on this item FOR (10,613 for, 0 against).

FOR: 10,613 (0.6%)ONE YEAR: 1,702,908 (99.3%)1-YEAR: 1,250 (0.1%)ONE VOTE: 418 (0.0%)

Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at JAZZ PHARMACEUTICALS PLC, 2024-2025
Asset manager	For	Vote
JPMorgan	0	One Year
APG Asset Management US Inc.	0	One Year
STOREBRAND ASSET MANAGEMENT AS	0	One Year
Empower	0	One Year
Desjardins Global Asset Management Inc.	0	One Year
TD ASSET MANAGEMENT INC	5,586	For
NORDEA INVESTMENT MANAGEMENT AB	4,984	For
GuideStone	0	One Year
Qtron Investments LLC	0	1-Year
Convergence Investment Partners, LLC	0	One Vote
CIDEL ASSET MANAGEMENT INC	0	One Year
PRINCETON CAPITAL MANAGEMENT LLC	43	For
BEACON INVESTMENT ADVISORY SERVICES, INC.	0	One Year

11. 14A Executive Compensation Vote Frequency

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2024-07-25.

100% fund support · no official result

ONE YEAR 82%1 YEAR 18%

The 7 asset managers below cast 100% of the shares they voted on this item FOR (1 for, 0 against).

FOR: 1 (0.1%)ONE YEAR: 1,087 (81.9%)1 YEAR: 239 (18.0%)3 YEARS: 1 (0.1%)

Largest asset managers voting on “14A Executive Compensation Vote Frequency” at JAZZ PHARMACEUTICALS PLC, 2024-2025
Asset manager	For	Vote
Claret Asset Management Corp	0	One Year
MQS Management LLC	0	1 Year
Focus Partners Wealth	0	1 Year
VOISARD ASSET MANAGEMENT GROUP, INC.	1	For
Williamson Legacy Group, LLC	0	3 Years
Blue Fin Capital, Inc.	0	--
Wallington Asset Management, LLC	0	--

12. Advisory Vote On Say On Pay Frequency: Please Vote For On This Resolution To Approve 1 Year

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2024-07-25.

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 6 asset managers below cast 100% of the shares they voted on this item FOR (696,533 for, 0 against).

FOR: 696,533 (100.0%)

Largest asset managers voting on “Advisory Vote On Say On Pay Frequency: Please Vote For On This Resolution To Approve 1 Year” at JAZZ PHARMACEUTICALS PLC, 2024-2025
Asset manager	For	Vote
BlackRock	602,732	For
Universal-Investment-Gesellschaft mbH	58,868	For
Robeco Institutional Asset Management B.V.	21,304	For
Raiffeisen Bank International AG	10,000	For
Universal-Investment-Luxembourg S.A.	3,517	For
SCHRODER INVESTMENT MANAGEMENT GROUP	112	For

13. Advisory Vote On Say On Pay Frequency: Please Vote For On This Resolution To Approve 2 Years

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2024-07-25.

— fund support · no official result

NOT VOTED 100%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

NOT VOTED: 93,801 (100.0%)

Largest asset managers voting on “Advisory Vote On Say On Pay Frequency: Please Vote For On This Resolution To Approve 2 Years” at JAZZ PHARMACEUTICALS PLC, 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Universal-Investment-Gesellschaft mbH	0	0	0	0	Not Voted
Robeco Institutional Asset Management B.V.	0	0	0	0	Not Voted
Raiffeisen Bank International AG	0	0	0	0	Not Voted
Universal-Investment-Luxembourg S.A.	0	0	0	0	Not Voted
SCHRODER INVESTMENT MANAGEMENT GROUP	0	0	0	0	Not Voted

14. Advisory Vote On Say On Pay Frequency: Please Vote For On This Resolution To Approve 3 Years

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2024-07-25.

— fund support · no official result

NOT VOTED 100%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

NOT VOTED: 93,801 (100.0%)

Largest asset managers voting on “Advisory Vote On Say On Pay Frequency: Please Vote For On This Resolution To Approve 3 Years” at JAZZ PHARMACEUTICALS PLC, 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Universal-Investment-Gesellschaft mbH	0	0	0	0	Not Voted
Robeco Institutional Asset Management B.V.	0	0	0	0	Not Voted
Raiffeisen Bank International AG	0	0	0	0	Not Voted
Universal-Investment-Luxembourg S.A.	0	0	0	0	Not Voted
SCHRODER INVESTMENT MANAGEMENT GROUP	0	0	0	0	Not Voted

15. Advisory Vote On Say On Pay Frequency: Please Vote For On This Resolution To Approve Abstain

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2024-07-25.

— fund support · no official result

NOT VOTED 100%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

NOT VOTED: 93,801 (100.0%)

Largest asset managers voting on “Advisory Vote On Say On Pay Frequency: Please Vote For On This Resolution To Approve Abstain” at JAZZ PHARMACEUTICALS PLC, 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Universal-Investment-Gesellschaft mbH	0	0	0	0	Not Voted
Robeco Institutional Asset Management B.V.	0	0	0	0	Not Voted
Raiffeisen Bank International AG	0	0	0	0	Not Voted
Universal-Investment-Luxembourg S.A.	0	0	0	0	Not Voted
SCHRODER INVESTMENT MANAGEMENT GROUP	0	0	0	0	Not Voted

16. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2025-07-24 (outside the 2024-2025 season's 1 July to 30 June window; reported in this season's filings).

Combines 2 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 48,261,149AGAINST: 2,887,574

JAZZ PHARMACEUTICALS PLC’s own tally for this item (“Proposal 3: to approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement”): 48,261,149 for, 2,887,574 against, per its Form 8-K filed 2025-07-25 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 62,255,000 outstanding shares: 78% for, 5% against (82% of the company cast a for/against vote).

The 2 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 579 against).

AGAINST 100%

AGAINST: 579 (100.0%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at JAZZ PHARMACEUTICALS PLC, 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Desjardins Global Asset Management Inc.	0	570	0	0	Against
Aletheian Wealth Advisors LLC	0	9	0	0	Against

17. Allot Securities

OTHER

Meeting held 2024-07-25.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (2 for, 0 against).

FOR: 2 (100.0%)

Largest asset managers voting on “Allot Securities” at JAZZ PHARMACEUTICALS PLC, 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
VOISARD ASSET MANAGEMENT GROUP, INC.	1	0	0	0	For
Williamson Legacy Group, LLC	1	0	0	0	For

18. Approve Motion to Adjourn Meeting

OTHER

Meeting held 2024-07-25.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (2 for, 0 against).

FOR: 2 (100.0%)

Largest asset managers voting on “Approve Motion to Adjourn Meeting” at JAZZ PHARMACEUTICALS PLC, 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
VOISARD ASSET MANAGEMENT GROUP, INC.	1	0	0	0	For
Williamson Legacy Group, LLC	1	0	0	0	For

19. Election of Directors (Majority Voting)

DIRECTOR ELECTIONS

Meeting held 2024-07-25.

All nominees (reported as one line). These filers reported the election of directors as a single line covering every nominee. It is not attributed to any one director, and no share total is shown for it.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR.

FOR: 100.0%

Largest asset managers voting on “Election of Directors (Majority Voting)” at JAZZ PHARMACEUTICALS PLC, 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
VOISARD ASSET MANAGEMENT GROUP, INC.	1	0	0	0	For
Williamson Legacy Group, LLC	1	0	0	0	For

20. Adjourn Meeting

CORPORATE GOVERNANCE

Meeting held 2024-07-25.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (36,717 for, 0 against).

FOR: 36,717 (100.0%)

Largest asset managers voting on “Adjourn Meeting” at JAZZ PHARMACEUTICALS PLC, 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Empower	33,385	0	0	0	For
GuideStone	3,332	0	0	0	For

21. Authorise Issue of Equity without Pre-emptive Rights

CAPITAL STRUCTUREMajority of the votes cast: yes

Meeting held 2024-07-25.

91% Majority: yes · of votes cast

FOR 91%9%

FOR: 52,568,310AGAINST: 5,308,898

The 2 asset managers below cast 100% of the shares they voted on this item FOR (36,717 for, 0 against).

FOR 100%

FOR: 36,717 (100.0%)

Largest asset managers voting on “Authorise Issue of Equity without Pre-emptive Rights” at JAZZ PHARMACEUTICALS PLC, 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Empower	33,385	0	0	0	For
GuideStone	3,332	0	0	0	For

22. SECTION 14A SAY-ON-PAY VOTES

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2024-07-25.

100% fund support · no official result

FOR 55%OTHER. SEE OTHER INFORMATION COLUMN 45%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (26 for, 0 against).

FOR: 26 (55.3%)OTHER. SEE OTHER INFORMATION COLUMN: 21 (44.7%)

Largest asset managers voting on “SECTION 14A SAY-ON-PAY VOTES” at JAZZ PHARMACEUTICALS PLC, 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Lido Advisors, LLC	26	0	0	0	For
Members Trust Co	0	0	0	0	Other. See Other Information Column

23. To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc's named executive officers as disclosed in the proxy statement.

SECTION 14A SAY-ON-PAY VOTES

Reported under meeting date 2023-08-03; no official results on file for that date (outside the 2024-2025 season's 1 July to 30 June window; reported in this season's filings).

Combines 2 wordings of this item as funds reported it.

0% fund support · no official result

AGAINST 100%

The 2 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 519 against).

AGAINST: 519 (100.0%)

Largest asset managers voting on “To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc's named executive of” at JAZZ PHARMACEUTICALS PLC, 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
COLDSTREAM CAPITAL MANAGEMENT INC	0	519	0	0	Against
Echo45 Advisors LLC	0	0	0	0	--

Largest JAZZ PHARMACEUTICALS PLC shareholders voting in 2024-2025

Ranked by the number of JAZZ PHARMACEUTICALS PLC shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 62,255,000 shares outstanding at the time of that meeting.

Top JAZZ PHARMACEUTICALS PLC shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	BlackRock	10.42%
2	Vanguard	10.30%
3	Capital Group	6.46%
4	Fidelity	4.49%
5	State Street	4.02%
6	LSV ASSET MANAGEMENT	2.66%
7	JPMorgan	2.30%
8	Pacer Funds Trust	2.22%
9	Vestal Point Capital, LP	2.15%
10	Baupost	2.05%

Reported JAZZ PHARMACEUTICALS PLC ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

JAZZ PHARMACEUTICALS PLC beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Vanguard Group	9.67%	13F
BlackRock	9.26%	13F
Dimensional Fund Advisors	3.74%	13F
State Street	3.16%	13F
JPMorgan Chase	2.67%	13F
Seamus Mulligan	2.09%	DEF14A
Renaissance Technologies	1.68%	13F
Bruce C. Cozadd	1.36%	DEF14A
Morgan Stanley	1.22%	13F
FMR (Fidelity)	1.22%	13F

Percentages above are of 62,255,000 shares outstanding, as reported by JAZZ PHARMACEUTICALS PLC on its Form 10-K dated 2023-12-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from JAZZ PHARMACEUTICALS PLC’s 10-K dated 2023-12-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At JAZZ PHARMACEUTICALS PLC's shareholder meeting held 2024-07-25, in the 2024-2025 proxy season, 551 asset managers reported how they voted in their SEC Form N-PX filings, covering 6,078 separate fund positions. Their filings are grouped here into 23 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc's… — FOR was 91% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: JAZZ PHARMACEUTICALS PLC's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-07-26.

JAZZ PHARMACEUTICALS PLC proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.